<p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家在微創微波消融（MWA）技術領域的市場領導者，今天宣佈與來自新西蘭的全資綜合投資管理企業 Stonewood Key Capital 建立戰略合作伙伴關係。這一合作將海南自由貿易港定位為公司跨境運營和供應鏈的關鍵樞紐，從而實現更高效的資本配置，加速其先進醫療解決方案在全球的商業化。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg"/></p>
<p>在正式簽署儀式上，這項協議鞏固了 Baird Medical 的市場領導地位，併成為其增長戰略的基石。通過利用自由貿易港在跨境資本流動和人員流動方面的有利政策，公司確保了一個旨在滿足對微創治療需求日益增長的競爭性運營框架，特別是針對甲狀腺及其他軟組織應用。</p>
<p>該合作利用了該地區集成的 “資本 - 基礎 - 服務” 生態系統，使 Baird Medical 能夠在更廣泛的醫療保健領域深化其影響力。</p>
<p>“這項合作代表了我們全球願景的延伸，而不僅僅是地理上的擴展，” Baird Medical 董事長吳海梅女士表示。“通過將自由貿易港定位為連接供應鏈韌性與醫療創新的關鍵樞紐，我們正在擴展我們的能力，以推動全球臨牀卓越。我們始終專注於賦能醫生，改善尋求高質量微創護理的患者的治療效果。”</p>
<p><strong>關於 Baird Medical</strong></p>
<p>Baird Medical 是一家前瞻性的醫療設備公司，專注於微創診斷和治療。公司致力於外科機器人系統和創新微創外科器械的研發。我們的使命是通過精確技術和先進的診斷解決方案提升患者的治療效果。公司將與領先的學術機構建立戰略合作關係。我們的願景超越外科輔助，旨在開發智能系統，主動指導診斷決策和預防醫療策略。作為一家獲得 FDA 510(k) 認證的醫療設備公司，Baird Medical 的解決方案已在美國超過 30 家知名醫院和診所中使用，包括梅奧診所、圖蘭大學醫學中心、哥倫比亞大學醫學中心、加州大學舊金山分校醫學中心、威爾康奈爾醫學中心和喬治華盛頓大學醫院。Baird Medical 在中國的甲狀腺微波消融設備和耗材市場也處於領先地位。同時，公司的微創治療產品正在逐步擴大在全球 20 多個國家的商業存在。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含某些不是歷史事實的聲明，而是根據 1995 年美國私人證券訴訟改革法案的安全港條款的前瞻性聲明。前瞻性聲明通常與未來事件或 Baird Medical 未來的財務或運營表現相關。在某些情況下，您可以通過諸如 “可能”、“可以”、“應該”、“期望”、“打算”、“可能”、“將”、“估計”、“預期”、“相信”、“預算”、“預測”、“打算”、“計劃”、“潛在”、“預測” 或 “繼續” 等術語，或這些術語的否定形式或變體或類似術語來識別前瞻性聲明。前瞻性聲明受到風險、不確定性和其他因素的影響，這些因素可能導致實際結果與這些前瞻性聲明所表達或暗示的結果有實質性差異。這些前瞻性聲明基於 Baird Medical 及其管理層認為合理的估計和假設，但本質上是不確定的。新的風險和不確定性可能會不時出現，無法預測所有風險和不確定性。您不應對本新聞稿中的前瞻性聲明過於依賴，這些聲明僅在作出時有效，並且完全受限於此處的警示聲明。Baird Medical 不承擔更新這些前瞻性聲明的任何義務。</p>
<p>實際結果可能因多種因素而與前瞻性聲明所表達或暗示的結果有實質性差異，包括但不限於：（1）Baird Medical 在中國或美國擴展業務可能不成功的風險；（2）一般經濟條件的變化；（3）監管條件和發展；（4）適用法律或法規的變化；（5）對 Baird Medical 或其他人提起的待決和未來訴訟及其他法律程序的性質、成本和結果；以及（6）在與業務合併和過渡報告相關的註冊聲明中不時描述的其他風險和不確定性，包括在標題為 “風險因素” 的部分中列出的風險，以及 ExcelFin 向 SEC 的其他文件。</p>
<p>上述因素列表並不排他。有關這些及其他風險因素的更多信息，請參閲 ExcelFin 最近向美國證券交易委員會（SEC）提交的文件，以及 Baird Medical 在與 ExcelFin 的業務合併中提交的註冊聲明。所有後續書面和口頭的前瞻性陳述，涉及 Baird Medical、本文所述的業務合併或其他歸因於 Baird Medical 或其代表的事項，均完全受到上述警示性聲明的限制。讀者被提醒不要對任何前瞻性陳述過度依賴，這些陳述僅在作出時有效。Baird Medical 明確聲明不承擔任何義務或承諾，公開發布任何前瞻性陳述的更新或修訂，以反映其預期的任何變化或任何基於的事件、條件或情況的變化。</p>
<p><strong>聯繫方式：</strong> Eric Huang，公關聯絡人</p>
<p>Baird Medical Investment Holdings Ltd.</p>
<p>電話：+1 (888) 508-6228</p>
<p>電子郵件：ir@bairdmed.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>來源 BDMD</p>

美國醫藥設備 ETF - iShares

BDMD

標普健康醫療設備 ETF - SPDR

<p>Baird Medical Investment Holdings Ltd.（納斯達克代碼：BDMD）宣佈與 Stonewood Key Capital 建立戰略合作伙伴關係，以增強其在微創微波消融技術的全球商業化努力。此次合作將利用海南自由貿易港優化資本配置，增強 Baird Medical 的市場地位。該合作旨在通過擴大對先進醫療解決方案的獲取來改善醫療結果。Baird Medical 因其創新的外科手術器械而受到認可，並在美國和中國擁有重要的市場份額</p>

<p>, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (&#34;Baird Medical&#34; or the &#34;Company&#34;), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced a strategic partnership with Stonewood Key Capital, a wholly-owned comprehensive investment management enterprise from New Zealand. This collaboration positions the Hainan Free Trade Port as a pivotal hub for the Company's cross-border operations and supply chain, enabling more efficient capital allocation to accelerate the commercialization of its advanced medical solutions globally.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD)（&#34;Baird Medical&#34;或&#34;公司&#34;）是一家在微創微波消融（MWA）技術領域的市場領導者，今天宣佈與來自新西蘭的全資綜合投資管理企業 Stonewood Key Capital 建立戰略合作伙伴關係。這一合作將海南自由貿易港定位為公司跨境運營和供應鏈的關鍵樞紐，從而實現更高效的資本配置，加速其先進醫療解決方案在全球的商業化。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg" alt="" original-src="https://mma.prnewswire.com/media/2868624/Baird_Medical_Investment_Holdings.jpg"/></p>
<p>Formalized at an official signing ceremony, this agreement reinforces Baird Medical's market leadership and serves as a cornerstone of its growth strategy. By capitalizing on the Free Trade Port's advantageous policies regarding cross-border capital flows and personnel mobility, the Company secures a competitive operational framework designed to meet rising demand for minimally invasive therapies addressing thyroid and other soft tissue applications.</p>
<div class="lb-trans"><p>在正式簽署儀式上，這項協議鞏固了 Baird Medical 的市場領導地位，併成為其增長戰略的基石。通過利用自由貿易港在跨境資本流動和人員流動方面的有利政策，公司確保了一個旨在滿足對微創治療需求日益增長的競爭性運營框架，特別是針對甲狀腺及其他軟組織應用。</p>
</div><p>The partnership utilizes the region's integrated &#34;Capital – Base-Service&#34; ecosystem, empowering Baird Medical to deepen its footprint in the broader healthcare sector.</p>
<div class="lb-trans"><p>該合作利用了該地區集成的 “資本 - 基礎 - 服務” 生態系統，使 Baird Medical 能夠在更廣泛的醫療保健領域深化其影響力。</p>
</div><p>&#34;This partnership represents an extension of our global vision rather than a mere geographic expansion,&#34; said Mrs. Haimei Wu, Chairwoman of Baird Medical. &#34;By positioning the Free Trade Port as a critical pivot point connecting supply chain resilience with medical innovation, we are expanding our capabilities to drive clinical excellence worldwide. Our focus remains steadfast on empowering physicians and improving outcomes for patients seeking high-quality, minimally invasive care.&#34;</p>
<div class="lb-trans"><p>“這項合作代表了我們全球願景的延伸，而不僅僅是地理上的擴展，” Baird Medical 董事長吳海梅女士表示。“通過將自由貿易港定位為連接供應鏈韌性與醫療創新的關鍵樞紐，我們正在擴展我們的能力，以推動全球臨牀卓越。我們始終專注於賦能醫生，改善尋求高質量微創護理的患者的治療效果。”</p>
</div><p><strong>About Baird Medical</strong></p>
<div class="lb-trans"><p><strong>關於 Baird Medical</strong></p>
</div><p>Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.</p>
<div class="lb-trans"><p>Baird Medical 是一家前瞻性的醫療設備公司，專注於微創診斷和治療。公司致力於外科機器人系統和創新微創外科器械的研發。我們的使命是通過精確技術和先進的診斷解決方案提升患者的治療效果。公司將與領先的學術機構建立戰略合作關係。我們的願景超越外科輔助，旨在開發智能系統，主動指導診斷決策和預防醫療策略。作為一家獲得 FDA 510(k) 認證的醫療設備公司，Baird Medical 的解決方案已在美國超過 30 家知名醫院和診所中使用，包括梅奧診所、圖蘭大學醫學中心、哥倫比亞大學醫學中心、加州大學舊金山分校醫學中心、威爾康奈爾醫學中心和喬治華盛頓大學醫院。Baird Medical 在中國的甲狀腺微波消融設備和耗材市場也處於領先地位。同時，公司的微創治療產品正在逐步擴大在全球 20 多個國家的商業存在。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as &#34;may&#34;, &#34;could&#34;, &#34;should&#34;, &#34;expect&#34;, &#34;intend&#34;, &#34;might&#34;, &#34;will&#34;, &#34;estimate&#34;, &#34;anticipate&#34;, &#34;believe&#34;, &#34;budget&#34;, &#34;forecast&#34;, &#34;intend&#34;, &#34;plan&#34;, &#34;potential&#34;, &#34;predict&#34;, or &#34;continue&#34;, or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.</p>
<div class="lb-trans"><p>本新聞稿包含某些不是歷史事實的聲明，而是根據 1995 年美國私人證券訴訟改革法案的安全港條款的前瞻性聲明。前瞻性聲明通常與未來事件或 Baird Medical 未來的財務或運營表現相關。在某些情況下，您可以通過諸如 “可能”、“可以”、“應該”、“期望”、“打算”、“可能”、“將”、“估計”、“預期”、“相信”、“預算”、“預測”、“打算”、“計劃”、“潛在”、“預測” 或 “繼續” 等術語，或這些術語的否定形式或變體或類似術語來識別前瞻性聲明。前瞻性聲明受到風險、不確定性和其他因素的影響，這些因素可能導致實際結果與這些前瞻性聲明所表達或暗示的結果有實質性差異。這些前瞻性聲明基於 Baird Medical 及其管理層認為合理的估計和假設，但本質上是不確定的。新的風險和不確定性可能會不時出現，無法預測所有風險和不確定性。您不應對本新聞稿中的前瞻性聲明過於依賴，這些聲明僅在作出時有效，並且完全受限於此處的警示聲明。Baird Medical 不承擔更新這些前瞻性聲明的任何義務。</p>
</div><p>Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled &#34;Risk Factors&#34; therein, and in ExcelFin's other filings with the SEC.</p>
<div class="lb-trans"><p>實際結果可能因多種因素而與前瞻性聲明所表達或暗示的結果有實質性差異，包括但不限於：（1）Baird Medical 在中國或美國擴展業務可能不成功的風險；（2）一般經濟條件的變化；（3）監管條件和發展；（4）適用法律或法規的變化；（5）對 Baird Medical 或其他人提起的待決和未來訴訟及其他法律程序的性質、成本和結果；以及（6）在與業務合併和過渡報告相關的註冊聲明中不時描述的其他風險和不確定性，包括在標題為 “風險因素” 的部分中列出的風險，以及 ExcelFin 向 SEC 的其他文件。</p>
</div><p>The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.</p>
<div class="lb-trans"><p>上述因素列表並不排他。有關這些及其他風險因素的更多信息，請參閲 ExcelFin 最近向美國證券交易委員會（SEC）提交的文件，以及 Baird Medical 在與 ExcelFin 的業務合併中提交的註冊聲明。所有後續書面和口頭的前瞻性陳述，涉及 Baird Medical、本文所述的業務合併或其他歸因於 Baird Medical 或其代表的事項，均完全受到上述警示性聲明的限制。讀者被提醒不要對任何前瞻性陳述過度依賴，這些陳述僅在作出時有效。Baird Medical 明確聲明不承擔任何義務或承諾，公開發布任何前瞻性陳述的更新或修訂，以反映其預期的任何變化或任何基於的事件、條件或情況的變化。</p>
</div><p><strong>Contact:</strong> Eric Huang, PR Liaison</p>
<div class="lb-trans"><p><strong>聯繫方式：</strong> Eric Huang，公關聯絡人</p>
</div><p>Baird Medical Investment Holdings Ltd.</p>
<div class="lb-trans"><p>Baird Medical Investment Holdings Ltd.</p>
</div><p>Phone: +1 (888) 508-6228</p>
<div class="lb-trans"><p>電話：+1 (888) 508-6228</p>
</div><p>Email: ir@bairdmed.com</p>
<div class="lb-trans"><p>電子郵件：ir@bairdmed.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2539350/Baird_Logo.jpg"/></p>
<p>SOURCE BDMD</p>
<div class="lb-trans"><p>來源 BDMD</p>
</div>

Baird Medical 通過與 Stonewood Key Capital 的戰略合作加速其全球商業計劃 | BDMD 股票新聞